TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Forte Biosciences ( (FBRX) ) just unveiled an announcement.
On June 23, 2025, Forte Biosciences announced positive results from its Phase 1b trial for FB102 in celiac disease, demonstrating significant benefits in histological and symptomatic endpoints. The company plans to initiate a Phase 2 trial with a topline readout expected in 2026, marking a significant step toward addressing unmet needs in celiac disease and potentially benefiting other indications like vitiligo, alopecia areata, and type 1 diabetes.
The most recent analyst rating on (FBRX) stock is a Buy with a $68.75 price target. To see the full list of analyst forecasts on Forte Biosciences stock, see the FBRX Stock Forecast page.
Spark’s Take on FBRX Stock
According to Spark, TipRanks’ AI Analyst, FBRX is a Underperform.
Forte Biosciences faces significant challenges with no revenue and increasing operational losses, leading to a weak financial performance. Technical analysis indicates a mixed outlook with bearish long-term trends. The negative P/E ratio and lack of dividend yield highlight valuation concerns. Without positive developments in these areas, the stock remains highly speculative and risky.
To see Spark’s full report on FBRX stock, click here.
More about Forte Biosciences
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate, for potentially broad autoimmune and autoimmune-related indications.
Average Trading Volume: 47,794
Technical Sentiment Signal: Hold
Current Market Cap: $96.51M
Find detailed analytics on FBRX stock on TipRanks’ Stock Analysis page.